Sirnaomics (2257) investor relations material

Executive summary

• Refined strategy prioritizes internal investment in oncology pipeline, with non-oncology assets advanced via partnerships and licensing.

• Focused R&D on dual delivery platforms (PNP and GalAhead™) and leveraging AI for candidate identification and development efficiency.

• Cost optimization and restructuring reduced administrative and R&D expenses, extending cash runway.

• No revenue generated; loss for the period significantly narrowed year-over-year.

Financial highlights

• Loss for the six months ended June 30, 2026 was US$0.4 million, down from US$3.4 million in the prior year period.

• Other income rose 13% to US$140,000, mainly from increased government grants.

• Other gains and losses increased to a gain of US$4.7 million, driven by a US$6.0 million gain on lease termination, offset by a US$1.3 million loss on disposal of property, plant and equipment.

• Administrative expenses decreased 16% to US$2.2 million; R&D expenses fell 33% to US$2.0 million.

• Net cash used in operating activities was US$4.8 million, a 2% reduction year-over-year.

• Cash and cash equivalents at June 30, 2026 were US$7.2 million, down from US$13.5 million at year-end 2025.

Outlook and guidance

• Strategic priorities for H2 2026 include launching pivotal trials for STP705, executing collaboration deals for non-core assets, and securing additional global partnerships.

• Continued focus on internal development of core oncology franchise and advancing preclinical assets for partnering.